Aura Biosciences Secures $8,000,000 New Funding Round

  • Feed Type
  • Date
    9/30/2016
  • Company Name
    Aura Biosciences
  • Mailing Address
    85 Bolton Street Cambridge, MA 02140 USA
  • Company Description
    Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration.
  • Website
    http://www.aurabiosciences.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $8,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from the financing will be used to advance to the clinic Aura’s lead program in ocular melanoma (OM), AU-011, which is the first targeted therapy ever to be developed for the primary treatment of this rare and life-threatening disease. AU-011 has been granted orphan drug designation by the U.S. Food and Drug Administration and is expected to enter clinical testing early next year.
  • M&A Terms
  • Venture Investor
    Advent International
  • Venture Investor
    Chiesi Ventures
  • Venture Investor
    Ysios Capital
  • Venture Investor
    Alexandria Venture Investments
  • Venture Investor
    Investor